IL17A and psoriasis: For instance, although our analysis showed that psoriasis received significantly less funding from the NIH relative to its disease burden, substantial funding from pharmaceutical companies has driven the development of innovative new drugs (ie, IL-23 and IL-17 inhibitors) that have transformed the treatment of psoriasis in recent years [9].